ArticlePharmaceutical research2012
Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Gas plasma-induced bacterial PAMP release promotes skin cancer cell death.Cell death & disease · 2025Article
- Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.International journal of molecular sciences · 2024Review
- Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer.Molecular therapy oncolytics · 2022Article
- Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystalsActa pharmaceutica Sinica. B · 2021Article
- Advances in technology and applications of nanoimmunotherapy for cancer.Biomarker research · 2021Review
- Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives.Journal of nanobiotechnology · 2021Review
- Haimufang decoction, a Chinese medicine formula for lung cancer, arrests cell cycle, stimulates apoptosis in NCI-H1975 cells, and induces M1 polarization in RAW 264.7 macrophage cells.BMC complementary medicine and therapies · 2020Article
- Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.Angewandte Chemie (International ed. in English) · 2019Review
- The era of bioengineering: how will this affect the next generation of cancer immunotherapy?Journal of translational medicine · 2017Review
- Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.Pharmaceutical research · 2017Article
- Modifying the tumor microenvironment using nanoparticle therapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Nanocarrier-based immunotherapy in cancer management and research.ImmunoTargets and therapy · 2014Review
- Sweeten PAMPs: Role of Sugar Complexed PAMPs in Innate Immunity and Vaccine Biology.Frontiers in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer is a multifactorial syndrome; hence, multidimensional therapy with a chemo-immunotherapeutic conjugate could be more effective in curing the disease.
methodsWe used SP-LPS, a bio-polymer having potent immunostimulatory activity, for conjugation with paclitaxel to make a chemo-immunotherapeutic conjugate. Its physicochemical characterization was done by HPLC, NMR and IR spectra. Stability was measured at different pH, temperature and in tissue homogenates. Chemotherapeutic and immunostimulatory activity was evaluated in vitro and also in tumor microenvironment.
resultsThe conjugate self assembled into nanoparticulate structure, probably due to micelle formation. Stability was pH and temperature dependent. The conjugate exhibited chemotherapeutic and immunotherapeutic activity in vitro. In vivo antitumor activity was significantly higher and a higher percentage of activated immune cells were found in the tumor microenvironment of the conjugate-treated mice as compared to Taxol®-treated group.
conclusionsThis conjugate is a potential chemo-immunotherapeutic compound for the treatment of cancer with advantages over present day chemotherapy with Taxol in terms of higher anticancer activity, less toxicity and ease of delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.